Cognitive & Nootropic / side effects and safety / Last reviewed 2026-06-02

Semax Side Effects: Safety Signals and Warnings

Semax safety concerns are compound-specific. The main listed side effects are Generally very well-tolerated, Mild headache, and Nasal dryness or irritation. The main warning signals are Most clinical evidence from Russian studies only, Not FDA-approved or independently validated, and May affect mood in individuals with bipolar disorder.

Read the full Semax guide Browse answer pages

Direct Answer

Evidence for Semax is too preliminary to support a research protocol with confidence outside Russia, where it holds regulatory approval for stroke and cognitive conditions based on smaller regional trials not replicated in Western Phase 3 settings. Of the Cognitive & Nootropic compounds, cerebrolysin has broader published human data as an alternative starting point.

Evidence grade
Level C
Research status
Phase 2
Category
Cognitive & Nootropic
Best for
Cognitive enhancement research, neuroprotection, BDNF pathway modulation

Reported Side Effects

Warnings

Known or Plausible Interactions

Regulatory Context

Approved as a pharmaceutical in Russia and some CIS countries. Not FDA-approved in the US. Available as a research peptide in Western countries. Not a controlled substance.

Evidence Snapshot

Evidence gradeLevel C
Research statusPhase 2
Best supported outcomesBDNF Elevation (Level B), Cognitive Enhancement (Level C), Stroke Recovery (Level C), and Neuroprotection (Level C)
Primary citation count2
Last reviewed2026-06-02

Related Guides

How to Cite This Page

ExaminePeptides. "Semax Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-02. https://examinepeptides.com/answers/semax-side-effects-safety/

This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.